DNLI

Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021

Denali Therapeutics (DNLI) is Overbought: Is A Drop Coming?

Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson's Disease

Denali Therapeutics Inc. (DNLI) Down 12.3% Since Last Earnings Report: Can It Rebound?